Homma et al. performed a phase I clinical study (DC/WT1-I/II) of treatment for patients with pancreatic ductal adenocarcinoma using DCs pulsed with a mixture of the same WT1 HLA class I and II peptides as those used in our study, combined with chemotherapy [30]. The gene discussed is WT1; the disease is pancreatic ductal adenocarcinoma.